Skip to main content
Interview with the Innovators
IWTI Best Practices in GU Navigation

A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer

Videos - Interview with the Innovators
Megan Price, MSN, APRN, FNP-C
Baylor Charles A. Sammons Cancer Center
Dallas, TX
Virginia Seery, MSN, RN, ANP-BC, AOCNP
Beth Israel Deaconess Medical Center
Boston, MA
Laura Wood, RN, MSN, OCN
Cleveland Clinic Taussig Cancer Center
Cleveland, OH
Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Related Items
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Videos published on November 12, 2025 in Interview with the Innovators
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
Jamie Carroll, APRN, CNP, MSN
Videos published on November 10, 2025 in Interview with the Innovators
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
Heather Moore, PharmD, BCOP, CPP
Videos published on November 5, 2025 in Interview with the Innovators
Insights From the TRADE Study: Optimizing Abemaciclib Dose Escalation for Better Tolerability and Adherence
Heather Moore, PharmD, BCOP, CPP
Videos published on November 3, 2025 in Interview with the Innovators
TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care
Erica Mayer, MD, MPH
Videos published on October 28, 2025 in Interview with the Innovators
Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability
Erica Mayer, MD, MPH
Videos published on October 24, 2025 in Interview with the Innovators
Importance of Hospital Partnerships for Bispecific Agent Implementation
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 21, 2025 in Interview with the Innovators
EHR Implementation of Bispecific Agents for Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 13, 2025 in Interview with the Innovators
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 10, 2025 in Interview with the Innovators
Clinical Pathways in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on February 27, 2025 in Interview with the Innovators